## REMARKS

Claims 1-26, as amended, appear in this application for the Examiner's review and consideration. The dependency of certain claims has been changed and the elected sequence has been recited in other claims. No new matter has been added.

In response to the Examiner's restriction requirement, applicants elect the invention of Group I, claims 1-11, drawn to an isolated polynucloeotide sequence, for examination in this application. In addition, claims 16-20 and 24-26 have been amended to depend directly or indirectly to claim 1, so that at least these claims should be examined with the elected claims of Group I.

It is submitted that all claims should be examined together as they now are related as compositions and method of using the same. For a complete examination of the composition claims, the methods also need to be reviewed to assure that the same compositions are not utilized. As the methods must be reviewed for that reason, it should not be an additional burden on the Examiner to evaluate the patentability of these methods. In addition, even if the method claims are withdrawn at this time, it is understood that those claims will be re-introduced and allowed when an allowable composition claim is found, in particular because claims 16 and 4 depend from claim 1.

Respectfully submitted,

Date

Allan A. Fanucci

(Reg. No. 30.256)

WINSTON & STRAWN LLP Customer No. 28765

212-294-3311

NY:1023369.1